These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34435356)

  • 21. Idelalisib: first global approval.
    Markham A
    Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
    Cheah CY; Nastoupil LJ; Neelapu SS; Forbes SG; Oki Y; Fowler NH
    Blood; 2015 May; 125(21):3357-9. PubMed ID: 25999447
    [No Abstract]   [Full Text] [Related]  

  • 25. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
    Kahl BS; Spurgeon SE; Furman RR; Flinn IW; Coutre SE; Brown JR; Benson DM; Byrd JC; Peterman S; Cho Y; Yu A; Godfrey WR; Wagner-Johnston ND
    Blood; 2014 May; 123(22):3398-405. PubMed ID: 24615778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
    Hewett YG; Uprety D; Shah BK
    J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
    Cramer P; von Tresckow J; Fink AM; Robrecht S; Giza A; Tausch E; Müller L; Knauf W; Zingerle M; Al-Sawaf O; Langerbeins P; Fischer K; Kreuzer KA; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
    Am J Hematol; 2024 Jun; 99(6):1192-1195. PubMed ID: 38578022
    [No Abstract]   [Full Text] [Related]  

  • 28. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
    Keating GM
    Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
    Lopez JP; Jimeno A
    Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.
    Machan S; Plaza C; Pérez-González Y; Rodriguez-Pinilla M; Requena L; Cordoba R
    J Med Case Rep; 2020 Feb; 14(1):35. PubMed ID: 32093776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.
    Okoli TC; Peer CJ; Dunleavy K; Figg WD
    Cancer Biol Ther; 2015; 16(2):204-6. PubMed ID: 25756507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
    Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.
    Sapon-Cousineau V; Sapon-Cousineau S; Assouline S
    Curr Treat Options Oncol; 2020 Apr; 21(6):51. PubMed ID: 32356174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 36. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
    Landsburg DJ; Barta SK; Ramchandren R; Batlevi C; Iyer S; Kelly K; Micallef IN; Smith SM; Stevens DA; Alvarez M; Califano A; Shen Y; Bosker G; Parker J; Soikes R; Martinez E; von Roemeling R; Martell RE; Oki Y
    Br J Haematol; 2021 Oct; 195(2):201-209. PubMed ID: 34341990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
    Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; Mclntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW
    Blood; 2016 May; 127(20):2411-5. PubMed ID: 26968534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
    Fruman DA; Cantley LC
    N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
    [No Abstract]   [Full Text] [Related]  

  • 40. Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report.
    Gabrielli G; Broccoli A; Pellegrini C; Argnani L; Cavo M; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e15-e17. PubMed ID: 31711891
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.